更强化治疗对衰弱多发性骨髓瘤患者可能更有效
该研究纳入2004至2020年美国退伍军人健康管理系统2573例新诊断多发性骨髓瘤患者(中位年龄69.7岁),比较硼替佐米-来那度胺-地塞米松(VRd)与来那度胺-地塞米松(Rd)的疗效。在倾向评分匹配人群中,VRd与Rd相比死亡风险更低(HR 0.81,95%CI 0.70-0.94),中度至重度衰弱患者关联最强(HR 0.74,95%CI 0.56-0.97)。
要点
- 匹配人群中VRd较Rd死亡风险更低(HR 0.81,95%CI 0.70-0.94)。
- 中度至重度衰弱患者VRd与Rd死亡风险关联最强(HR 0.74,95%CI 0.56-0.97)。
- VRd较Rd总体住院发生率略高,但该关联在中度至重度衰弱患者中减弱。
核心结论
- 研究结果证实美国退伍军人中VRd较Rd的获益,并进一步提示该获益在衰弱程度最高的患者中最强,作者认为更强化治疗骨髓瘤可能更有效治疗衰弱本身。
研究设计与样本
- 回顾性识别2004至2020年美国退伍军人健康管理系统2573例新诊断多发性骨髓瘤患者,中位年龄69.7岁,其中VRd组990例、Rd组1583例。
- 使用退伍军人事务衰弱指数评估衰弱,按骨髓瘤分期和倾向评分1:1匹配以减少混杂不平衡。
主要发现
- 中度至重度衰弱患者较非衰弱患者III期骨髓瘤和骨髓瘤相关衰弱缺陷的患病率更高。
- 总体匹配人群中,VRd与Rd相比死亡风险更低(HR 0.81,95%CI 0.70-0.94)。
- 中度至重度衰弱患者中VRd与Rd的死亡风险关联最强(HR 0.74,95%CI 0.56-0.97),轻度衰弱者关联减弱(HR 0.80,95%CI 0.61-1.05),非衰弱者关联减弱(HR 0.86,95%CI 0.67-1.10)。
- 总体人群中VRd与Rd相比住院发生率略高,但该关联在中度至重度衰弱患者中减弱。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although randomized controlled trial data suggest that the more intensive triplet bortezomib-lenalidomide-dexamethasone (VRd) is superior to the less intensive doublet lenalidomide-dexamethasone (Rd) in patients newly diagnosed with multiple myeloma (MM), guidelines have historically recommended Rd over VRd for patients who are frail and may not tolerate a triplet. We identified 2573 patients (median age, 69.7 years) newly diagnosed with MM who were initiated on VRd (990) or Rd (1583) in the national US Veterans Affairs health care System from 2004 to 2020. We measured frailty using the Veterans Affairs Frailty Index. To reduce imbalance in confounding, we matched patients for MM stage and 1:1 based on a propensity score. Patients who were moderate-severely frail had a higher prevalence of stage III MM and myeloma-related frailty deficits than patients who were not frail. VRd vs Rd was associated with lower mortality (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.70-0.94) in the overall matched population. Patients who were moderate-severely frail demonstrated the strongest association (HR 0.74; 95% CI, 0.56-0.97), whereas the association weakened in those who were mildly frail (HR, 0.80; 95% CI, 0.61-1.05) and nonfrail (HR, 0.86; 95% CI, 0.67-1.10). VRd vs Rd was associated with a modestly higher incidence of hospitalizations in the overall population, but this association weakened in patients who were moderate-severely frail. Our findings confirm the benefit of VRd over Rd in US veterans and further suggest that this benefit is strongest in patients with the highest levels of frailty, arguing that more intensive treatment of myeloma may be more effective treatment of frailty itself.
引用
- DuMontier C, La J, Bihn J, et al. More intensive therapy as more effective treatment for frail patients with multiple myeloma [corrected]. Blood Adv. 2023. PMID: 37582048. doi:10.1182/bloodadvances.2023011019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。